Cargando…

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features

Detalles Bibliográficos
Autores principales:	Li, Mingxiao, Ren, Xiaohui, Dong, Gehong, Wang, Jincheng, Jiang, Haihui, Yang, Chuanwei, Zhao, Xuzhe, Zhu, Qinghui, Cui, Yong, Yu, Kefu, Lin, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171117/ https://www.ncbi.nlm.nih.gov/pubmed/34094991 http://dx.doi.org/10.3389/fonc.2021.700599

Ejemplares similares

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
por: Jiang, Haihui, et al.
Publicado: (2021)

Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications
por: Jiang, Haihui, et al.
Publicado: (2020)

Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis
por: Yang, Chuanwei, et al.
Publicado: (2021)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
por: Yang, Chuanwei, et al.
Publicado: (2022)

T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination
por: Li, Mingxiao, et al.
Publicado: (2022)

Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences
por: Wang, Wesley, et al.
Publicado: (2023)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma
por: Koh, Sabrina P., et al.
Publicado: (2017)

Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation
por: Ehret, Felix, et al.
Publicado: (2023)

Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation
por: Qian, Xiaohua, et al.
Publicado: (2016)

Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
por: Verma, Gaurav, et al.
Publicado: (2018)

Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma
por: El-Abtah, Mohamed E, et al.
Publicado: (2022)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns
por: Lo, Chung-Ming, et al.
Publicado: (2020)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
por: Moassefi, Mana, et al.
Publicado: (2022)

Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
por: Li, Mingxiao, et al.
Publicado: (2022)

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
por: Polivka, J., et al.
Publicado: (2014)

A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis
por: Conte, Brianna, et al.
Publicado: (2022)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults
por: King-Stephens, David
Publicado: (2022)

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report
por: Nishimura, Shunsuke, et al.
Publicado: (2023)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma
por: Daghighi, Shadi, et al.
Publicado: (2020)

Characterization and clinical implications of different malignant transformation patterns in diffuse low‐grade gliomas
por: Jiang, Haihui, et al.
Publicado: (2023)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

A prognostic estimation model based on mRNA-sequence data for patients with oligodendroglioma
por: Zhu, Qinghui, et al.
Publicado: (2022)

A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression
por: Zhang, Peng, et al.
Publicado: (2015)

Glioblastoma with brainstem leptomeningeal pseudoprogression following radiation therapy
por: Kinger, Nikhar, et al.
Publicado: (2019)

Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas
por: Wang, Pu, et al.
Publicado: (2012)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4f9kpc2ao3a9ar6v0g834gms3a